Fangda advised QuantumPharm on the offering. QuantumPharm Inc. was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited and launched a globally...
You must be a Standard 1 Year member to access this content.
Fangda advised Swire Group on the deal. Swire Group finalized the acquisition of the controlling shares of DeltaHealth China Limited from Eight Roads. DeltaHealth specializes in cardiovascular...
You must be a Standard 1 Year member to access this content.
Fangda represented Shanghai Brattea Medical Technology Co., Ltd. on the deal. Shanghai Brattea Medical Technology Co., Ltd. completed its series D investment round. The transaction was...
You must be a Standard 1 Year member to access this content.
Fangda advised AnHeart Therapeutics on the deal. Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...
You must be a Standard 1 Year member to access this content.
Fangda Partners assisted Voneseals Technology (Shanghai) Inc. on the transaction. Voneseals Technology (Shanghai) Inc. completed the acquisition of a 51% equity stake in Shanghai Garnor Sealing Technology...
You must be a Standard 1 Year member to access this content.
DeHeng Hong Kong advised Anji Qicai Lingfeng Rural Tourism Investment Co., Ltd on the deal. Anji Qicai Lingfeng Rural Tourism Investment Co., Ltd completed the issuance...
You must be a Standard 1 Year member to access this content.
DeHeng Law Offices (Hong Kong) LLP advised Zhenjiang Culture & Broadcasting Industry Group Co., Ltd. on the deal. Zhenjiang Culture & Broadcasting Industry Group completed the issuance of...
You must be a Standard 1 Year member to access this content.
Fangda advised Jiangsu Aisen Semiconductor Material on the deal. Jiangsu Aisen Semiconductor Material Co., Ltd. completed its successful listing on the STAR Market of the Shanghai...
You must be a Standard 1 Year member to access this content.
Norton Rose Fulbright and Fangda Partners advised Deutsche Bank Aktiengesellschaft on the issuance. Deutsche Bank Aktiengesellschaft completed the issuance of its second Panda bond with a volume...
You must be a Standard 1 Year member to access this content.
Fangda represented HLC on the deal. Viva Biotech Holdings Group completed the equity financing at both Viva Holdings and its subsidiary Viva Biotech (Shanghai) Ltd., bringing in...
You must be a Standard 1 Year member to access this content.
Fangda advised SanegeneBio on the deal. Suzhou Sanegene Bio Inc. announced its strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of...
You must be a Standard 1 Year member to access this content.
Fangda advised WuXi XDC Cayman Inc. on the deal. WuXi XDC Cayman Inc. successfully spun-off from WuXi Biologics (Cayman) Inc. for a separate listing on the Main...
You must be a Standard 1 Year member to access this content.
